arrow
A

Amanda Nizam

Cleveland Clinic Foundation
H指数:12
被引数:1,006

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CLINICAL AND GENOMIC CHARACTERIZATION OF HER2 EXPRESSION IN PLASMACYTOID UROTHELIAL CARCINOMA: INSIGHTS FROM A LARGE INSTITUTIONAL COHORT

人瘤样尿路上皮癌中HER2表达的临床和基因组特征:来自大型机构队列的见解

2026-05-010
PRE
CIRCULATING TUMOR DNA AS A BIOMARKER FOR UPSTAGING AND ADVERSE PATHOLOGY IN HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER

循环肿瘤DNA作为高风险非肌层浸润性膀胱癌升级和不良病理的生物标志物

2026-05-010
PRE
Trimodality Therapy for Bladder Cancer: A Single Institution Retrospective Analysis of Factors Associated With Outcomes for High-Risk Patients Undergoing Organ-Sparing Therapy

膀胱癌的三联疗法:对接受器官保留疗法的高风险患者结局相关因素的单机构回顾性分析

2026-02-010
PRE
Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study

在恩沃利单抗之后的尿路上皮癌患者中,萨cituzumab govitecan的疗效:UNITE研究的分析

2025-12-010
OAAI
Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study

FGFR3突变型晚期尿路上皮癌中,erdafitinib在enfortumab vedotin治疗前或治疗后的疗效:UNITE协作研究的分析

2025-11-010
PRE
Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study

接受恩沃利单抗维多汀治疗的晚期尿路上皮癌患者中的治疗相关不良事件及关联结局:UNITE研究的分析

2025-10-020
OAAI
Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study

恩福妥单抗(Enfortumab Vedotin)在具有不同组织学亚型的晚期尿路上皮癌患者中的疗效:UNITE研究的分析

2025-09-140
PRE
Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data

与恩夫妥单抗韦汀疗效相关的基因组生物标志物:对UNITE研究数据的分析

2024-12-011
OAAI
Pre-treatment (Tx) risk factors for enfortumab vedotin-induced peripheral neuropathy (EVIPN) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of UNITE

恩沃利单抗 vedotin(Enfortumab vedotin)诱导的外周神经病变(EVIPN)在晚期尿路上皮癌(aUC)患者中的预处理(Tx)危险因素:UNITE 分析

2024-09-010
PRE
Efficacy of enfortumab vedotin (EV) in patients (pts) with (w) advanced urothelial carcinoma (aUC) who have baseline neuropathy (N) and/or diabetes mellitus (DM): A UNITE study analysis

恩诺妥昔单抗(EV)在具有基线神经病变(N)和/或糖尿病(DM)的晚期尿路上皮癌(aUC)患者(pts)中的疗效:一项UNITE研究的分析

2024-09-010
PRE
Patients Recently Treated for B-lymphoid MalignanciesShow Increased Risk of Severe COVID-19

最近接受B淋巴恶性肿瘤治疗的患者出现严重新型冠状病毒肺炎的风险增加

2022-03-0913
OA
Geriatric risk factors for serious COVID-19 outcomes among older adults with cancer: a cohort study from the COVID-19 and Cancer Consortium

老年癌症患者严重新型冠状病毒肺炎结局的老年危险因素: 来自新型冠状病毒肺炎和癌症协会的队列研究

2022-03-0115
OA
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study
CANCER
IF5.1
2021-12-0954
OAAI
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

癌症患者的临床因素和近期抗癌治疗与新型冠状病毒肺炎严重程度的关系: 新型冠状病毒肺炎和癌症协会的报告

2021-06-01237
OAAI